Outbreaks of carbapenem-resistant A. baumannii in healthcare facilities have been reported in Europe and worldwide.
Infections with carbapenem-resistant A. baumannii occur in patients with severe underlying diseases, mainly in intensive care units, and are often related to invasive procedures or indwelling devices. However, such infections are increasingly being reported in patients admitted to conventional medical/surgical wards and A. baumannii is difficult to eradicate once it has become endemic.
While carbapenems traditionally were the antibiotics of choice for treatment of A. baumannii infections, resistance to these drugs has led to increased use of colistin as last-line treatment. Although still rare, resistance to colistin in A. baumannii is also increasingly being reported in Europe.
This is a significant threat to patients and healthcare systems in all EU/EEA countries and the risks need to be reduced through clinical management, prevention of transmission in hospitals and other healthcare settings, prevention of cross-border transmission, and improvement of preparedness of EU/EEA countries.
For more information on Anti-Microbial Resistance on the ecdc.europa.eu website